Ibrance (palbociclib) is a small molecule pharmaceutical. Palbociclib was first approved as Ibrance on 2015-02-03. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against cyclin-dependent kinase 4 and cyclin-dependent kinase 6. Ibrance's patents are valid until 2036-05-24 (FDA).
|Drug Class||Cyclin dependent kinase inhibitors|